Medicine News and Research

RSS

MRI-guided SLAH procedure provides safe, effective alternative to surgery

For patients with mesial temporal lobe epilepsy (MTLE) that can't be controlled by medications, a minimally invasive laser procedure performed under MRI guidance provides a safe and effective alternative to surgery, suggests a study in the June issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

3 Jun 2014

Nonadherence triples relapse risk in African American and Asian children in remission from ALL

An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published online today in Blood, the Journal of the American Society of Hematology.

3 Jun 2014

Oncologists urged to consider financial impact of treatments

The American Society of Clinical Oncology is developing a system to rate drugs for advanced cancer based on their likely benefits and side effects, as well as on their price. Meanwhile, better long-term care is urged for the millions who survive the disease and a report details how drugmakers are tailoring treatments to individuals' genetic makeups even though that may affect only small numbers of people.

3 Jun 2014

Enzalutamide drug proves effective in stemming progression of prostate cancer

A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University.

3 Jun 2014

Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

Jazz Pharmaceuticals plc today presented data from the Phase 2b study evaluating JZP-110 (formerly known as ADX-N05) as a potential new treatment for the symptoms of excessive daytime sleepiness (EDS) in adults with narcolepsy.

3 Jun 2014

EHR solutions provider, ChartLogic, partners with Kareo

ChartLogic, a leader in electronic health record solutions for specialty and primary care physician practices, today announced a partnership with billing solutions powerhouse, Kareo, that will allow the company to offer its clients best-of-breed revenue cycle management.

2 Jun 2014

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.

2 Jun 2014

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Alkermes plc today announced the initiation of the second phase 2 study of ALKS 3831, a novel, oral, broad-spectrum antipsychotic medicine in development for schizophrenia.

2 Jun 2014

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

2 Jun 2014

Physicians Interactive eCoupon now available within Greenway Health's PrimeSUITE EHR system

Physicians Interactive, the leading provider of online and mobile clinical resources and solutions for healthcare professionals (HCPs), today announced that its eCoupon automated voucher and coupon distribution solution is now available within the latest version of Greenway Health's PrimeSUITE electronic health record (EHR) system.

2 Jun 2014

First Edition: June 2, 2014

Today's headlines include reports about state health law implementation activities as well as the next steps regarding the difficulties at the VA health system.

2 Jun 2014

Yale researchers find that hormone leptin may help treat metabolic disorders

Twenty years after the hormone leptin was found to regulate metabolism, appetite, and weight through brain cells called neurons, Yale School of Medicine researchers have found that the hormone also acts on other types of cells to control appetite.

2 Jun 2014

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

2 Jun 2014

$Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma$

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine.

2 Jun 2014

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis announced today the results of a pivotal Phase II trial demonstrating that patients with locally advanced (laBCC) or metastatic basal cell carcinoma (mBCC) taking the investigational oral compound LDE225 (sonidegib) had marked and sustained tumor shrinkage after a median follow-up of 13.9 months.

2 Jun 2014

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Many people with cystic fibrosis develop diabetes. The reasons for this have been largely unknown, but now researchers at Lund University in Sweden and  Karolinska institutet have identified a molecular mechanism that contributes to the raised diabetes risk.

2 Jun 2014

Compound in saliva may protect from toxins in tea, coffee and liquid smoke flavoring

A compound in saliva, along with common proteins in blood and muscle, may protect human cells from powerful toxins in tea, coffee and liquid smoke flavoring, according to results of a new study led by investigators at the Johns Hopkins Kimmel Cancer Center.

2 Jun 2014

Risk of death following surgery is highest on weekends, in the afternoons and February

New research presented at this year's Euroanaesthesia show that on weekends, in the afternoons and in February are the times when the risk of death following surgery is the highest.

2 Jun 2014

Individuals who speak more languages may slow down cognitive decline from aging

New research reveals that bilingualism has a positive effect on cognition later in life. Findings published in Annals of Neurology, a journal of the American Neurological Association and Child Neurology Society, show that individuals who speak two or more languages, even those who acquired the second language in adulthood, may slow down cognitive decline from aging.

2 Jun 2014

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according to a multicenter interim study published in the OnLine First edition of the New England Journal of Medicine.

2 Jun 2014

Medicine News and Research

MRI-guided SLAH procedure provides safe, effective alternative to surgery

Nonadherence triples relapse risk in African American and Asian children in remission from ALL

Oncologists urged to consider financial impact of treatments

Enzalutamide drug proves effective in stemming progression of prostate cancer

Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

EHR solutions provider, ChartLogic, partners with Kareo

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Physicians Interactive eCoupon now available within Greenway Health's PrimeSUITE EHR system

First Edition: June 2, 2014

Yale researchers find that hormone leptin may help treat metabolic disorders

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Compound in saliva may protect from toxins in tea, coffee and liquid smoke flavoring

Risk of death following surgery is highest on weekends, in the afternoons and February

Individuals who speak more languages may slow down cognitive decline from aging

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

Everything there is to know about biosimilars eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News